There are 2949 resources available
1340P - Real-world treatment patterns and outcomes in patients (pts) with advanced, ALK+ non-small cell lung cancer (NSCLC) in Europe
Presenter: Nikolay Stoyanov
Session: E-Poster Display
Resources:
Abstract
1341P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations
Presenter: James Chih-Hsin Yang
Session: E-Poster Display
Resources:
Abstract
1342P - Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study
Presenter: Diansheng Zhong
Session: E-Poster Display
Resources:
Abstract
1343P - Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients (START-TKI study)
Presenter: G.D. Marijn Veerman
Session: E-Poster Display
Resources:
Abstract
1344P - The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry
Presenter: Markus Falk
Session: E-Poster Display
Resources:
Abstract
1345P - Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
Presenter: Zofia Piotrowska
Session: E-Poster Display
Resources:
Abstract
1346P - Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
Presenter: Juergen Wolf
Session: E-Poster Display
Resources:
Abstract
1347P - Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
Presenter: Marina Garassino
Session: E-Poster Display
Resources:
Abstract
1348P - Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
Presenter: Byong Chul Cho
Session: E-Poster Display
Resources:
Abstract
1349P - Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Presenter: Nicolas Girard
Session: E-Poster Display
Resources:
Abstract